MLICM
ALDX icon

Metropolitan Life Insurance Company (MetLife)’s Aldeyra Therapeutics ALDX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-197
Closed -$644 – 88
2024
Q1 		$644 Buy
197
+20
+11% +$66 ﹤0.01% 2303
2023
Q4 		$621 Sell
177
-2,381
-93% -$7.35K ﹤0.01% 2335
2023
Q3 		$17.1K Hold
2,558
– – ﹤0.01% 1970
2023
Q2 		$21.5K Buy
+2,558
New +$25.2K ﹤0.01% 1894
2022
Q2 		– Sell
-3,570
Closed -$15.9K – 2369
2022
Q1 		$15.9K Sell
3,570
-1,791
-33% -$7.13K ﹤0.01% 2190
2021
Q4 		$21.4K Sell
5,361
-3,732
-41% -$28.5K ﹤0.01% 2751
2021
Q3 		$79.8K Sell
9,093
-5,487
-38% -$50.4K ﹤0.01% 2644
2021
Q2 		$165K Buy
+14,580
New +$175K ﹤0.01% 2287

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ALDX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Aldeyra Therapeutics (ALDX) in Q2 2024, closing a stake of 197 shares — an estimated $644 sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ALDX in Q2 2021 and held it in 8 quarters. The position peaked at $165K in Q2 2021. 103 funds tracked by Wall St. Rank hold ALDX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Aldeyra Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 197 Aldeyra Therapeutics shares in Q2 2024, an estimated $644.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 8 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Aldeyra Therapeutics position peaked at $165K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.